Coultreon Biopharma: Funding, Investors & Team (Sep 2026)
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology with best-in-class therapeutics.
Coultreon Biopharma has raised $125M across 1 funding round on record, the most recent a Series A of $125M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Coultreon Biopharma Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Coultreon Biopharma Funding Rounds
Coultreon Biopharma Founders and Leadership Team
Contact details for the Coultreon Biopharma team: 1 of 1 has an email address on file.
Start 14-day free trial →Coultreon Biopharma Funding Compared to Other Biotechnology Startups
Coultreon Biopharma's latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Coultreon Biopharma in Biotechnology and Heverlee
Companies Similar to Coultreon Biopharma
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
Coultreon Biopharma Funding FAQs
What does Coultreon Biopharma do?
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology with best-in-class therapeutics.
How much funding has Coultreon Biopharma raised?
Coultreon Biopharma has raised $125M across 1 round on record. The most recent is a Series A of $125M announced in Apr 2026.
When did Coultreon Biopharma last raise funding?
Coultreon Biopharma's most recent funding round on record is a Series A of $125M, announced in Apr 2026.
Who founded Coultreon Biopharma?
FundedIQ lists Pierre Raboisson (Founder) at Coultreon Biopharma.
Where is Coultreon Biopharma headquartered?
Coultreon Biopharma is based in Heverlee, Vlaams-Brabant, Belgium.
How many employees does Coultreon Biopharma have?
Coultreon Biopharma is in the 11-50 employee band.
How does Coultreon Biopharma's funding compare to other Biotechnology startups?
Coultreon Biopharma's latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Coultreon Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Coultreon Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.